Company Overview of Allergan, Inc.
Allergan, Inc. discovers, develops, and commercializes pharmaceuticals, biologics, medical devices, and over-the-counter products in the Unites States and internationally. It operates through two segments, Specialty Pharmaceuticals and Medical Devices. The Specialty Pharmaceuticals segment produces a range of pharmaceutical products, including, ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy, and retinal disease; Botox for therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth, other prescription, and over-the-counter skin care products; and urology products. The Medical Devices segment provides a range of medical devices com...
400 Interpace Parkway
Morris Corporate Center III
Parsippany, NJ 07054
Founded in 1948
Key Executives for Allergan, Inc.
Chairman and Chief Executive Officer
Chief Financial Officer and Executive Vice President of Finance & Business Development
Chief Scientific Officer and Executive Vice President of Research & Development
Principal Accounting Officer, Senior Vice President and Corporate Controller
Compensation as of Fiscal Year 2015.
Allergan, Inc. Key Developments
NuMedii, Inc. Announces Research Collaboration with Allergan to Explore New Treatments for Psoriasis
Sep 29 15
NuMedii, Inc. announced the formation of a research alliance with Allergan to explore new therapeutic options for the potential treatment of psoriasis. The companies will use NuMedii's predictive Big Data intelligence platform technology, which enables the discovery of new uses for medicines across a number of therapeutic areas. NuMedii has already generated multiple lead compounds/candidates by utilizing its data intelligence technology for psoriasis, which will be the focus of the research alliance with Allergan. Under the terms of the agreement governing the research alliance, NuMedii will provide Allergan with proprietary, de-risked therapeutic candidates for psoriasis that are compatible with the 505b2 drug development regulatory pathway. NuMedii and Allergan may select and evaluate lead candidates in proof-of-concept disease models for potential further development. NuMedii's proprietary and dynamic Big Data technology consists of hundreds of millions of human, biological, pharmacological and clinical data points that NuMedii has normalized and annotated. NuMedii integrates these data with proprietary network-based algorithms to find both drug candidates and biomarkers predictive of efficacy for diseases. In 2013, NuMedii entered into a strategic technology partnership with the Intellectual Property and Life Science business of Thomson Reuters, creating an unprecedented repository of content and methodologies to systematically identify new applications for existing drug compounds. NuMedii is initially using its Big Data technology to discover and de-risk new indications for safe, existing drugs.
Allergan Ceases Operations at its Generic Manufacturing and Packaging Facility in Iceland from 2016
Jul 3 15
Allergan announced that operations at its generic manufacturing and packaging facility in Iceland are to cease from 2016. The first phase of transferring manufacturing capacity to other production units will commence in the third quarter of 2016. According to a company statement, published on 29 June, the transition of manufacturing production to other sites, probably in Europe and Asia, is expected to be completed by mid-2017. However, Allergan's manufacturing site, which produces a reported 1.5 billion generic drugs per year, accounts for a large percentage of these export statistics. The decision to close the facility is therefore significant for the small, but domestically important, pharmaceutical sector.
Allergan Inc. Plans to Cut 577 Jobs at Irvine Headquarters
Apr 23 15
Allergan Inc. will lay off 577 workers from its Irvine headquarters effective June 4. In July 2014, the company announced it would shed 1,500 jobs, or 13% of its worldwide workforce, in an attempt to fend off a hostile $52 billion bid from Valeant Pharmaceuticals. This month's notice brings the total number of jobs cut since then to 1,491, nearly all in Irvine.
Similar Private Companies By Industry
Recent Private Companies Transactions
November 17, 2014